Acrivon Therapeutics Inc.... (ACRV)
NASDAQ: ACRV
· Real-Time Price · USD
1.36
-0.03 (-2.16%)
At close: Aug 15, 2025, 3:59 PM
1.38
1.10%
After-hours: Aug 15, 2025, 05:51 PM EDT
Acrivon Therapeutics Common Stock Income Statement
Financials in USD. Fiscal
year is
undefined.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 |
Revenue | n/a | n/a | 848K | n/a | n/a | n/a | 1.88M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | 311K | 303K | 300K | 200K | 224K | 149K | 331K | 295K | 316K | 313K | 300K | 259K | 223K | n/a | 261K |
Gross Profit | n/a | -311K | 424K | -300K | -200K | -224K | -149K | -331K | -295K | -316K | -313K | -300K | -259K | -223K | n/a | -261K |
Operating Income | -22.65M | -21.66M | -24.95M | -25.14M | -21.44M | -17.67M | -21.05M | -16.14M | -15.52M | -14.39M | -9.95M | -9.57M | -5.92M | -7.21M | -4.27M | -2.67M |
Interest Income | 1.73M | 2M | 2.36M | 2.7M | 2.69M | 1.45M | n/a | 1.77M | 1.77M | 1.81M | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -21.01M | -19.68M | -22.83M | -22.44M | -18.8M | -16.49M | -19.25M | -14.47M | -13.91M | -12.76M | -8.93M | -9.2M | -5.82M | -7.22M | -4.34M | -2.44M |
Net Income | -21.01M | -19.68M | -22.83M | -22.44M | -18.8M | -16.49M | -19.25M | -14.47M | -13.91M | -11.12M | -7.91M | -8.82M | -5.71M | -7.23M | -4.42M | -2.21M |
Selling & General & Admin | 6.47M | 6.25M | 6.32M | 6.28M | 6.41M | 6.2M | 5.58M | 6M | 5M | 4.63M | 4.08M | 1.63M | 1.85M | 1.14M | 1.22M | 455K |
Research & Development | 16.18M | 15.41M | 18.33M | 18.86M | 15.03M | 11.25M | 15.33M | 9.88M | 10.52M | 9.76M | 5.86M | 7.94M | 4.08M | 6.07M | 3.05M | 2.22M |
Other Expenses | n/a | -311K | n/a | n/a | -200K | n/a | n/a | n/a | 1.61M | 1.64M | 1.02M | 377K | 105K | -8K | n/a | 231K |
Operating Expenses | 22.65M | 21.35M | 24.65M | 25.14M | 21.24M | 17.44M | 20.9M | 15.88M | 15.52M | 14.39M | 9.95M | 9.57M | 5.92M | 7.21M | 4.27M | 2.67M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | 1.64M | n/a | n/a | n/a | n/a | n/a | n/a | 8K | 73K | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | n/a | 21.66M | 24.95M | 25.14M | 21.44M | 17.67M | 21.05M | 16.14M | 15.52M | 14.39M | 9.95M | 9.57M | 5.92M | 7.21M | 4.27M | 2.67M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 6.92K | -1.64M | -1.02M | -377K | -105K | 8K | 73K | -231K |
Shares Outstanding (Basic) | 38.46M | 38.35M | 38.24M | 38.11M | 36.13M | 22.59M | 22.34M | 22.08M | 21.97M | 21.92M | 20.88M | 18.81M | 12.91M | 12.91M | 12.91M | 12.91M |
Shares Outstanding (Diluted) | 38.46M | 38.35M | 38.24M | 38.11M | 36.13M | 22.59M | 22.34M | 22.08M | 21.97M | 21.92M | 20.88M | 18.81M | 12.91M | 12.91M | 12.91M | 12.91M |
EPS (Basic) | -0.55 | -0.51 | -0.6 | -0.59 | -0.52 | -0.73 | -0.86 | -0.66 | -0.63 | -0.51 | -0.38 | -0.47 | -0.44 | -0.56 | -0.34 | -0.17 |
EPS (Diluted) | -0.55 | -0.51 | -0.6 | -0.59 | -0.52 | -0.73 | -0.86 | -0.66 | -0.63 | -0.51 | -0.38 | -0.47 | -0.44 | -0.56 | -0.34 | -0.17 |
EBITDA | -22.65M | -21.66M | -24.65M | -24.89M | -12.57M | -17.44M | -20.9M | -14.13M | -15.52M | -14.39M | -9.82M | -9.46M | -5.85M | -7M | -4.26M | -2.66M |
EBIT | n/a | -19.68M | -24.95M | -25.14M | -12.79M | -17.67M | -21.05M | -14.47M | -15.52M | -14.39M | -9.95M | -9.57M | -5.92M | -7.21M | -4.27M | -2.67M |
Depreciation & Amortization | n/a | 311K | 303K | 300K | 228K | 224K | 149K | 331K | 295K | 316K | 313K | 300K | 259K | 223K | 13K | 261K |